Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R)...

Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on
Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline

SEATTLE, Dec. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTAX: CTIC) management to hold a conference call tomorrow
(Thursday, December 27) at 8:30 am EST to discuss update on Zevalin asset
purchase, CMS reimbursement, and PIX301 timing for results.
Conference Call Numbers
Thursday, December 27
8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific
800-218-0204
303-262-2130

Webcast available at
http://www.cticseattle.com -
webcast will be archived approximately two hours after call ends.

Call-back numbers for post listening available at 10:00 am Eastern
800-405-2236
303-590-3000
Passcode: 11105647

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
Susan Callahan
T: 206.272.4472
F: 206.272.4434
E: media@ctiseattle.com
http://www.cticseattle.com/media.htm

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.cticseattle.com/investors.htm

SOURCE Cell Therapeutics, Inc.

media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200, or Susan Callahan,
+1-206-272-4472, fax, +1-206-272-4434, media@ctiseattle.com, or investors,
Leah Grant, +1-206-282-7100, fax, +1-206-272-4434, invest@ctiseattle.com, all
of Cell Therapeutics, Inc.